← ANALYST RATINGS · TIPRANKS
Cencora (COR): analyst forecast and price target
Analyst consensus
Moderate Buy8 Buy3 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $366, the highest $400, the lowest $330. The average is +7.4% from the last price of $341.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DistributionxAI Grok-3 | TipRanks - xAI | $381 → $380−0.3% | Buy | +11.5% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI DeepSeek Medical - DistributionDeepSeek R1-0528 | TipRanks - DeepSeek | $376 → $375−0.3% | Buy | +10.0% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI PerPlexity Medical - DistributionPerPlexity SonarPro | TipRanks - PerPlexity | $369 → $368−0.3% | Hold | +7.9% | Downgrade | 17.10.26on TipRanks 13:05 | — | |
| AI OpenAI Medical - DistributionOpenAI 4o | TipRanks - OpenAI | $338 → $372+10.1% | Hold | +9.1% | Downgrade | 16.10.26on TipRanks 08:05 | — | |
| AI Anthropic Medical - DistributionAnthropic Opus-4.1 | TipRanks - Anthropic | $327 → $360+10.1% | Hold | +5.6% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI Google Medical - DistributionGemini 2.5Pro | TipRanks - Google | $347 → $382+10.1% | Buy | +12.0% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $430 → $400−7.0% | Buy | +17.3% | Reiterated | 16.10.26on TipRanks 08:00 | +1.0% | ↗ |
| Unknown Analyst | Leerink Partners | $380 → $388+2.1% | Buy | +13.8% | Reiterated | 07.10.26on TipRanks Oct 14 21:00 | +0.5%next day +1.7% · 5 days +6.9% | ↗ |
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $330 | Hold | −3.2% | Reiterated | 06.10.26on TipRanks 21:45 | +0.5%next day +1.7% · 5 days +6.9% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $350 | Buy | +2.7% | Reiterated | 13.08.26on TipRanks Aug 14 04:35 | −2.0%next day +1.6% · 5 days +3.7% | ↗ |
| Elizabeth Anderson CFA★★★★★★★★★★#2664 · hits 55% · avg +4.4% | Evercore ISI | $350 | Buy | +2.7% | Reiterated | 13.08.26on TipRanks 10:15 | −2.0%next day +1.6% · 5 days +3.7% | ↗ |
| Allen Lutz★★★★★★★★★★#598 · hits 67% · avg +12.3% | Bank of America Securities | $310 → $330+6.5% | Hold | −3.2% | Reiterated | 12.08.26on TipRanks Aug 13 06:50 | −6.2%next day −2.0% · 5 days +1.6% | ↗ |
| Stephen Baxter★★★★★★★★★★#3289 · hits 50% · avg +3.9% | Wells Fargo | $331 → $395+19.3% | Buy | +15.9% | Assigned | 11.08.26on TipRanks 06:55 | +3.0%next day −6.2% · 5 days −4.7% | ↗ |
| Lisa Gill★★★★★★★★★★#1237 · hits 58% · avg +9.0% | J.P. Morgan | $390 | Buy | +14.4% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | +1.4%next day +3.0% · 5 days −3.6% | ↗ |
| Charles Rhyee★★★★★★★★★★#1937 · hits 54% · avg +5.6% | TD Cowen | $400 | Buy | +17.3% | Reiterated | 09.08.26on TipRanks Aug 10 03:05 | +1.4%next day +3.0% · 5 days −3.6% | ↗ |
| Erin Wright★★★★★★★★★★#354 · hits 64% · avg +15.1% | Morgan Stanley | $342 → $346+1.2% | Buy | +1.5% | Assigned | 07.08.26on TipRanks 08:20 | −2.0%next day +1.4% · 5 days −2.3% | ↗ |
| Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% | Robert W. Baird | $340 → $370+8.8% | Buy | +8.5% | Reiterated | 06.08.26on TipRanks 09:25 | +2.6%next day −2.0% · 5 days −5.8% | ↗ |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $355 → $370+4.2% | Buy | +8.5% | Reiterated | 06.08.26on TipRanks 06:50 | +2.6%next day −2.0% · 5 days −5.8% | ↗ |
| Ryan Daniels★★★★★★★★★★#2878 · hits 48% · avg +5.8% | William Blair | — | Hold | — | Reiterated | 05.08.26on TipRanks 09:10 | +3.8%next day +2.6% · 5 days −1.3% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $400 | Buy | +17.3% | Reiterated | 17.03.26on TipRanks Mar 18 08:10 | −3.5%next day −1.5% · 5 days +0.1% | ↗ |
| Brian Tanquilut★★★★★★★★★★#1681 · hits 52% · avg +6.6% | Jefferies | $330 → $440+33.3% | Buy | +29.1% | Upgrade | 22.01.26on TipRanks 06:00 | −0.3%next day +0.2% · 5 days −0.8% | ↗ |
| George Hill★★★★★★★★★★#1126 · hits 54% · avg +9.0% | Deutsche Bank | $322 → $371+15.2% | Buy | +8.8% | Reiterated | 07.11.25on TipRanks 15:55 | 0.0%next day −0.5% · 5 days +0.4% | ↗ |
| Steven Valiquette★★★★★★★★★★#8240 · hits 53% · avg 0.0% | Mizuho Securities | $340 → $380+11.8% | Buy | +11.5% | Reiterated | 06.11.25on TipRanks 07:15 | +2.8%next day 0.0% · 5 days +1.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Cencora
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $369 at a price of $300 (+23.0%); now: $368 at $341 (+8.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 1 | 0 | 0 |
| Buy | 13 | 11 | 8 | 11 | 10 | 11 |
| Hold | 6 | 6 | 8 | 8 | 8 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $4.58 (from $4.53 to $4.62). Last quarter: $4.48.
Sales
Next quarter’s sales estimate — $88.0B (from $86.7B to $88.7B). Last quarter: $84.8B.
Best top-analyst consensus in the sector · Healthcare
About Cencora
- CEO: Robert Mauch
- Employees: 49,000
- 1 West First Avenue, Conshohocken, PA, 19428-1800, US
- www.cencora.com
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospit
Data from the stock’s TipRanks forecast page, read 56 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗